Burns
Conditions
Keywords
Vitamin K
Brief summary
The use of Vitamin K in treating bleeding diatheses is well documented and accepted as standard of care, as is the effect of Vitamin K on calcium and bone metabolism. In the treatment of larger burns however, there is a paucity of available literature related to optimal daily dosing, goals of therapy and potential complications. This study aims to identify any potential issues arising from the administration of a standard of care dose in an historical cohort of subjects with larger burns to a prospective patient population given a decreasing dose during their intensive care unit (ICU) stay.
Detailed description
This will be a prospective, single-center study. Eligible subjects will present with a minimum 20% Total Body Surface Area (TBSA) burn injury and expected to receive the standard dose of intravenous Vitamin K (10mg/day). Exclusion criteria will include any patient admitted with a history of, or having present at baseline: bleeding disorders, thrombocytopenia, coagulopathy, or liver dysfunction (MELD Score ≥20). Subjects who are moribund, or in the opinion of the investigator, not expected to survive will be excluded, as well as burns induced as a result of a suicide attempt. The study will enroll approximately 25 subjects in the prospective arm and 25 subjects will be matched from our medical record data base to the basic subject criteria for the chart review portion of the study. Study duration will be 90 days. The research foundation will request exemption, waiver of HIPAA (Health Insurance Portability and Accountability Act) authorization and waiver of informed consent for the data collection /cohort portion of the study as only burn injury demographics, lab results and dosing regimen will be collected. No protected health information (PHI) will be recorded on patients identified for the cohort arm of the study.
Interventions
DRUGVitamin K
Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
Sponsors
Joseph M. Still Research Foundation, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single-center, prospective interventional study to compare a decreasing dose of daily Vitamin K to a matched retrospective cohort
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The Subject: 1. is anticipated to be hospitalized for the duration of treatment. 2. is ≥18 years of age. 3. or their legally authorized representative is able to provide informed consent. 4. has been diagnosed with at least 20%TBSA thermal, chemical, or electrical burn. 5. has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy)? 6. is expected to receive the standard of care dosing of intravenous Vitamin K (10g/day).
Exclusion criteria
* The Subject: 1. has a history or, or has present at baseline any of the following: 1. bleeding disorders 2. thrombocytopenia 3. coagulopathy 2. liver failure (MELD -Model for end stage liver disease score ≥20) 3. is already therapeutically anticoagulated for PE, DVT, etc. 4. is participating in another interventional clinical trial for the duration of the study. 5. is moribund, or in the opinion of the investigator is not expected to survive. 6. has a burn injury sustained as a result a suicide attempt. Historical Cohort Inclusion/Exclusion All criteria will be the same except there will be no informed consent requirement. The data collection portion in the historical cohort will be to match burn size, type and etiologies and to collect lab results and other outcomes as specified in the study objectives. No PHI will be collected or shared. Additionally, only patients that received intravenous Vitamin K 10m/day for at least 14 days will be chosen for data collection. Every attempt will be made to match study drug duration (90days) as closely as possible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary outcome for the study will be rate of DVT occurrence | 90 days or the study will end at time of discharge or death. | This outcome will be measured in patients with larger burn % total body surface area (TBSA) burn injury receiving Vitamin K 10mg/day with a decreasing dose over 5 days and maintaining a lower daily dose, versus an historical cohort that received intravenous Vitamin K 10m/day during their entire intensive care unit (ICU) stay. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The secondary outcome for this study will be total number of blood products transfused (Fresh Frozen Plasma - FFP and Packed Red Blood Cells - PRBCs. | 90 days or the study will end at time of discharge or death. | This outcome will be measured in patients with larger burn % TBSA receiving Vitamin K 10mg/day with a decreasing dose over 5 days and maintaining a lower daily dose, versus an historical cohort that received intravenous Vitamin K 10m/day during their entire ICU stay |
| The secondary outcome for this study will be comparison of coagulopathy patterns | 90 days or the study will end at time of discharge or death. | This outcome will be measured in patients with larger burn % TBSA receiving Vitamin K 10mg/day with a decreasing dose over 5 days and maintaining a lower daily dose, versus an historical cohort that received intravenous Vitamin K 10m/day during their entire ICU stay as evidenced by changes in: (Protime - PT, Partial Thromboplastin Time - PTT and International Normalized Ration - INR, liver function abnormalities (Serum glutamic pyruvic transaminase - SGPT, Serum glutamic oxaloacetic transaminase - SGOT, Albumin , Bilirubin). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent adverse events to determine safety and tolerability | from time consent is signed throughout the duration of active study participation (90 days, discharge or death - whichever comes first) | This outcome will be measured in patients with larger burn % TBSA receiving Vitamin K 10mg/day with a decreasing dose over 5 days and maintaining a lower daily dose, versus an historical cohort that received intravenous Vitamin K 10m/day during their entire ICU stay. |
Countries
United States
Contacts
Primary ContactJoan M Wilson, MSN, MHA, RN
Backup ContactTammy Taylor
Outcome results
None listed